Death rates associated with patients with refractory angina, or chronic chest pain, are lower than previously considered; therefore, physicians should focus on relieving the chest pain symptoms and improving the quality of life in these patients according to an article published online this week in the European Heart Journal.
[More]
Neovasc Inc., today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.
[More]
A new stress test protocol that investigates reducing the use of perfusion imaging in low risk patients undergoing SPECT myocardial perfusion imaging for possible angina symptoms was found to be diagnostically safe, revealed a US retrospective analysis.
[More]
L-carnitine significantly improves cardiac health in patients after a heart attack, say a multicenter team of investigators in a study published today in Mayo Clinic Proceedings.
[More]
The American College of Physicians today unveiled two evidence-based interventions and two videos to improve the health outcomes of patients in the first year following an initial acute coronary syndrome event such as heart attack and unstable angina (chest pain or discomfort but no part of the heart muscle dies), the most common indications of ACS.
[More]
Two innovative techniques in the placement of an implanted spinal cord stimulator (SCS) are expected to reduce common complications at the implant site, according to new research revealed today.
[More]
CryoLife, Inc., a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received U.S. Food and Drug Administration 510(k) clearance for a next generation HeRO (Hemodialysis Reliable Outflow) device.
[More]
GE Healthcare today announced that it has submitted an application to amend its European Marketing Authorisation that will allow the company to manufacture Optison 0.19 mg/ml dispersion for injection within its own facility.
[More]
Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes.
[More]
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.
[More]
For the third year in a row, the Cedars-Sinai Heart Institute and Comprehensive Transplant Center performed more adult heart transplants than any other U.S. medical center, according to statistics compiled by the United Network for Organ Sharing, the nonprofit organization that manages the nation's transplant system.
[More]
Eli Lilly and Company presented results today at the annual European Association of Urology Congress in Milan, Italy, of a study that showed Cialis 5 mg once daily co-administered with finasteride significantly improved scores on the International Prostate Symptom Score, compared to placebo/finasteride, in men with lower urinary tract symptoms of benign prostatic hyperplasia and enlarged prostates.
[More]
Higher levels of pregnancy-associated plasma protein A were associated with an increased risk of cardiovascular events in people with cardiac chest pain that developed as a result of heart disease/coronary artery disease, according to a study published in CMAJ.
[More]
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
Americans work longer hours, take fewer vacation days, and retire later than employees in other industrialized countries around the globe.
[More]
The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures.
[More]
A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal.
[More]
With shared decision making, patients and their clinicians collaboratively review the risks and benefits of available treatments options while also considering the patients' preferences and values.
[More]